Profile data is unavailable for this security.
About the company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
- Revenue in USD (TTM)349.64m
- Net income in USD-143.59m
- Incorporated2017
- Employees436.00
- LocationBeam Therapeutics Inc238 Main StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 327-8775
- Fax+1 (302) 655-5049
- Websitehttps://beamtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xencor Inc | 85.16m | -198.24m | 1.69bn | 280.00 | -- | 2.33 | -- | 19.80 | -3.20 | -3.20 | 1.37 | 10.35 | 0.0967 | -- | 2.61 | 304,157.20 | -22.89 | -3.70 | -24.90 | -4.12 | -- | -- | -236.81 | -15.92 | -- | -- | 0.0243 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -110.55m | 1.72bn | 148.00 | -- | 1.92 | -- | -- | -2.21 | -2.21 | 0.00 | 15.66 | 0.00 | -- | -- | 0.00 | -19.23 | -- | -20.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Arvinas Inc | 161.10m | -308.60m | 1.73bn | 445.00 | -- | 2.94 | -- | 10.71 | -4.79 | -4.79 | 2.38 | 8.53 | 0.1448 | -- | 14.01 | 362,022.50 | -27.73 | -22.01 | -37.81 | -26.47 | -- | -- | -191.56 | -316.55 | -- | -- | 0.001 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Celldex Therapeutics, Inc. | 9.98m | -154.08m | 1.74bn | 160.00 | -- | 2.21 | -- | 174.37 | -2.57 | -2.57 | 0.164 | 11.85 | 0.0181 | -- | 18.07 | 62,350.00 | -27.93 | -29.65 | -29.53 | -31.42 | -- | -- | -1,544.48 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Fortrea Holdings Inc | 2.77bn | -233.60m | 1.75bn | 15.50k | -- | 1.16 | -- | 0.6297 | -2.62 | -3.40 | 31.09 | 16.87 | 0.6954 | -- | 3.20 | 154,155.60 | -5.85 | -- | -7.29 | -- | 18.49 | -- | -8.42 | -- | -- | -0.6141 | 0.4263 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Disc Medicine Inc | 0.00 | -103.48m | 1.89bn | 74.00 | -- | 4.04 | -- | -- | -3.97 | -3.97 | 0.00 | 15.73 | 0.00 | -- | -- | 0.00 | -23.74 | -- | -24.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| MannKind Corp | 267.20m | 21.57m | 1.90bn | 414.00 | 97.02 | -- | 67.65 | 7.12 | 0.0711 | 0.0711 | 0.9277 | -0.7612 | 0.6812 | 2.79 | 13.36 | 645,410.60 | 5.50 | -26.07 | 7.00 | -37.80 | 71.91 | 59.68 | 8.07 | -57.61 | 4.17 | 1.89 | 1.77 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Beam Therapeutics Inc | 349.64m | -143.59m | 1.95bn | 436.00 | -- | 2.46 | -- | 5.58 | -1.72 | -1.72 | 4.27 | 9.58 | 0.284 | -- | -- | 801,933.50 | -11.67 | -24.54 | -13.84 | -29.26 | -- | -- | -41.07 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Mirum Pharmaceuticals Inc | 307.03m | -99.81m | 2.07bn | 311.00 | -- | 8.99 | -- | 6.76 | -2.12 | -2.12 | 6.51 | 4.84 | 0.4657 | 3.83 | 5.28 | 1,162,985.00 | -15.14 | -38.93 | -17.70 | -44.88 | 72.68 | -- | -32.51 | -190.71 | 3.15 | -- | 0.5701 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Wave Life Sciences Ltd | 53.61m | -142.52m | 2.09bn | 266.00 | -- | 15.03 | -- | 38.97 | -1.11 | -1.11 | 0.427 | 1.01 | 0.192 | -- | 15.32 | 201,541.40 | -51.04 | -56.98 | -99.07 | -102.38 | -- | -- | -265.84 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| CG Oncology Inc | 684.00k | -78.29m | 2.17bn | 61.00 | -- | 4.07 | -- | 3,171.45 | -1.19 | -1.19 | 0.0104 | 7.95 | 0.0018 | -- | 9.91 | 11,213.12 | -18.93 | -- | -19.63 | -- | -- | -- | -10,578.22 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Akero Therapeutics Inc | 0.00 | -237.22m | 2.18bn | 60.00 | -- | 2.94 | -- | -- | -3.75 | -3.75 | 0.00 | 10.61 | 0.00 | -- | -- | 0.00 | -32.66 | -37.73 | -34.35 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0454 | -- | -- | -- | -35.46 | -- | -- | -- |
| Keros Therapeutics Inc | 651.00k | -181.57m | 2.18bn | 160.00 | -- | 3.97 | -- | 3,350.11 | -5.21 | -5.21 | 0.0187 | 13.57 | 0.0014 | -- | -- | 4,786.77 | -40.10 | -35.95 | -42.23 | -38.07 | -- | -- | -27,890.94 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Azenta Inc | 656.32m | -164.17m | 2.23bn | 3.30k | -- | 1.17 | -- | 3.39 | -2.97 | -2.97 | 12.31 | 38.82 | 0.2633 | 3.23 | 3.71 | -- | -6.59 | -2.07 | -7.18 | -2.31 | 40.13 | 43.11 | -25.01 | -8.76 | 3.50 | -- | -- | -- | -1.32 | -3.41 | -1,174.32 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Beam Therapeutics Inc's reporting currency: US Dollar USD
53.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Farallon Capital Management LLCas of 30 Sep 2024 | 8.21m | 9.96% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 7.72m | 9.37% |
| ARK Investment Management LLCas of 30 Sep 2024 | 6.53m | 7.93% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.03m | 7.32% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 3.93m | 4.77% |
| Nikko Asset Management Americas, Inc.as of 30 Sep 2024 | 3.55m | 4.31% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 2.87m | 3.48% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 30 Sep 2024 | 1.81m | 2.20% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.81m | 2.19% |
| Redmile Group LLCas of 30 Sep 2024 | 1.61m | 1.96% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
